Adaptimmune Therapeutics (ADAP)
0.46
-0.00 (-0.37%)
At close: Mar 13, 2025, 11:47 AM
Adaptimmune Therapeutics Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Net Income | -113.87M | -165.46M | -158.09M | -130.09M | -137.16M | -95.51M | -70.14M | -71.58M | -23.69M | -14.37M | -9.34M |
| Depreciation & Amortization | 9.45M | 6.08M | 6.57M | 7.59M | 8.01M | 7.81M | 5.42M | 3.29M | 732.78K | 250.37K | 45.6K |
| Stock-Based Compensation | 11.77M | 18.24M | 20.63M | 10.41M | 11.05M | n/a | 10.8M | 8.82M | 4.22M | 349.15K | 170.26K |
| Other Working Capital | -25.05M | -1.53M | 134.63M | 56.05M | 4.72M | -45.34M | 7.21M | 12.5M | -13.74M | 49.78M | 904.52K |
| Other Non-Cash Items | -23.19M | 903K | 1.17M | -55K | -185K | 237K | 341K | -1.19M | -257.89K | 1.7K | 457.58K |
| Deferred Income Tax | n/a | n/a | 5.82M | 2.5M | 1.06M | 12.22M | -7.95M | n/a | n/a | 1.22M | -0.00 |
| Change in Working Capital | -25.05M | -1.53M | 134.63M | 56.05M | 4.72M | -45.34M | 7.21M | 12.5M | -13.74M | 49.78M | 904.52K |
| Operating Cash Flow | -140.88M | -141.77M | 10.73M | -53.59M | -112.51M | -104.39M | -54.31M | -48.17M | -32.74M | 37.23M | -7.77M |
| Capital Expenditures | -4.88M | -29.74M | -8.78M | -2.91M | -3.07M | -4.71M | -25.01M | -12.79M | -5.11M | -1.45M | -159.62K |
| Acquisitions | 45.26M | 77.86M | 207K | 565K | 1.48M | 798K | 369K | 1.28M | n/a | n/a | n/a |
| Purchase of Investments | -75.95M | -48.12M | -139.76M | -381.04M | -27.28M | -150.79M | -171.33M | -42.84M | -55.3M | n/a | n/a |
| Sales Maturities Of Investments | 210.98M | 166.99M | 224.34M | 105.02M | 125.3M | 138.04M | 69.72M | 73.38M | n/a | n/a | n/a |
| Other Investing Acitivies | 925K | -77.86M | -207K | -565K | -1.48M | -798K | 181K | -1.28M | 124.23K | n/a | n/a |
| Investing Cash Flow | 176.54M | 89.14M | 75.8M | -278.92M | 94.94M | -17.46M | -126.08M | 17.75M | -60.28M | -1.45M | -159.62K |
| Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.29M |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 256K | 50K | 759K | 5.66M | 366K | 102.69M | 401K | 17K | 175.99M | -159.05M | -10.81M |
| Financial Cash Flow | 880K | 12.87M | 3.29M | 340.05M | 366K | 102.69M | 103.57M | 17K | n/a | 16.94M | 3.71M |
| Net Cash Flow | 37.41M | -42.06M | 90.18M | 6.58M | -17.57M | -15.82M | -74.5M | -35.98M | 181.72M | 52.72M | -4.22M |
| Free Cash Flow | -145.76M | -171.51M | 1.95M | -56.5M | -115.58M | -109.1M | -79.33M | -60.95M | -37.85M | 35.78M | -7.92M |